- Home
- DBI vs NTHI Comparison
DBI vs NTHI Comparison
Compare DBI & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- NTHI
- Stock Information
- Founded
- DBI 1991
- NTHI 2008
- Country
- DBI United States
- NTHI United States
- Employees
- DBI N/A
- NTHI N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- DBI Consumer Discretionary
- NTHI Health Care
- Exchange
- DBI Nasdaq
- NTHI Nasdaq
- Market Cap
- DBI 137.2M
- NTHI 118.5M
- IPO Year
- DBI 1991
- NTHI N/A
- Fundamental
- Price
- DBI $3.30
- NTHI $7.34
- Analyst Decision
- DBI Hold
- NTHI
- Analyst Count
- DBI 2
- NTHI 0
- Target Price
- DBI $4.75
- NTHI N/A
- AVG Volume (30 Days)
- DBI 1.5M
- NTHI 81.7K
- Earning Date
- DBI 06-03-2025
- NTHI 01-01-0001
- Dividend Yield
- DBI 6.07%
- NTHI N/A
- EPS Growth
- DBI N/A
- NTHI N/A
- EPS
- DBI N/A
- NTHI N/A
- Revenue
- DBI $3,009,262,000.00
- NTHI $83,000.00
- Revenue This Year
- DBI $2.22
- NTHI N/A
- Revenue Next Year
- DBI $2.18
- NTHI N/A
- P/E Ratio
- DBI N/A
- NTHI N/A
- Revenue Growth
- DBI N/A
- NTHI N/A
- 52 Week Low
- DBI $2.44
- NTHI $4.11
- 52 Week High
- DBI $11.06
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- DBI 57.04
- NTHI N/A
- Support Level
- DBI $2.78
- NTHI N/A
- Resistance Level
- DBI $3.38
- NTHI N/A
- Average True Range (ATR)
- DBI 0.17
- NTHI 0.00
- MACD
- DBI 0.11
- NTHI 0.00
- Stochastic Oscillator
- DBI 90.00
- NTHI 0.00
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").